Ep. 45 What Should Happen After a Dezawa Muse Stem Cell Injection?

Ep. 45 What Should Happen After a Dezawa Muse Stem Cell Injection?

What Should Happen After a Dezawa Muse Stem Cell Injection? Most of the attention in regenerative medicine falls on the treatment itself. The decision to pursue therapy. The consultation. The injection. And then, for many patients, a period of uncertainty — because no one has clearly explained what comes next. At STEMS Health in Miami Beach, Drs. Ankeet Choxi and Jarred Mait treat that post-procedure period as a clinical phase in its own right. What happens in the weeks and months following a Dezawa Muse stem cell injection is not a passive waiting period. It is an active phase of biological activity — one that is shaped by patient behavior, clinical oversight, and the structure of follow-up care. Understanding the timeline begins with a foundational concept: the injection is the beginning of the regenerative process, not its conclusion. In the first week after a Muse cell injection, the biological focus is on the early tissue response. Some mild soreness, local swelling, or increased awareness of the injection area is normal and expected. It reflects the body's response to both the procedural intervention and the cellular activity beginning at the target site. This is not a sign that something has gone wrong. In most cases, it is a sign that the tissue is responding. During this window, certain medications warrant particular attention. Systemic corticosteroids and specific anti-inflammatory agents can blunt the early regenerative response — the same response that Muse cell therapy is designed to initiate. At STEMS Health, patients receive specific guidance on which medications to avoid and for how long. They are also given clear parameters for what warrants a call to the practice: significant or worsening swelling beyond 72 hours, fever or systemic symptoms, new neurological findings, or any change that falls outside the expected pattern. Weeks two through six represent what clinicians at STEMS Health describe as the early regenerative window. During this period, cell homing and early differentiation are most active. Many patients begin noticing incremental shifts — changes in pain levels, modest improvements in mobility or function, or simply a sense that something in the treated area is different. The progression is rarely linear. Some patients experience a temporary increase in awareness of the treatment area before improvement becomes consistent. That pattern is recognized and expected. A structured clinical check-in during this window is not optional in the STEMS Health model. It is a deliberate assessment — an opportunity for the treating physicians to evaluate whether the response is tracking appropriately and whether any modification to the patient's activity protocol or rehabilitation guidance is warranted. For most musculo-skeletal conditions, the primary improvement arc unfolds between weeks six and sixteen. This is the period when tissue remodeling and structural repair — stimulated by Muse cell activity — become measurable through both patient-reported outcomes and clinical examination. Patients who have followed activity guidance, maintained appropriate anti-inflammatory management, and stayed engaged with follow-up appointments during this window consistently demonstrate better outcomes than those who have not. Engagement during the regenerative window is not incidental to the result. It is part of the treatment. For neurological conditions, complex degenerative presentations, or patients who received combination protocols, the relevant timeline extends further. Neurological regeneration is a slow, staged biological process. Progress may not be dramatic in the early months, and the absence of dramatic change should not be interpreted as treatment failure. At STEMS Health, longer-term follow-up is structured around the specific condition and clinical trajectory of each patient. Every patient treated at STEMS Health receives a post-procedure care plan before leaving the practice. It is not a general handout. It is a personalized document built around the patient's specific condition, the procedure that was performed, and the recovery timeline appropriate to their clinical profile. Follow-up appointments are scheduled, not left to the patient to initiate. The physicians remain accessible between appointments for questions or concerns that arise outside the scheduled intervals. Patients evaluating regenerative medicine providers should ask explicitly what the post-procedure protocol includes — how often they will be seen, what is being monitored, and how the practice responds if progress deviates from expected benchmarks. A provider whose post-procedure care is clearly defined and clinically structured is a provider whose commitment to the outcome extends beyond the procedure itself. The regenerative process requires time, appropriate clinical conditions, and physician oversight that does not end when the needle is withdrawn. At STEMS Health, that oversight is designed into the treatment model — because the outcome of a Muse cell injection is shaped as much by what follows as by the injection itself.

Ep 44 How to Identify Authentic Dezawa MuseCells®: Why Verification Matters More Than Ever

To learn more about regenerative and restorative stem cell therapy treatments, visit www.stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565. ------------- How to Know if Your Dezawa MuseCells® Are Authentic As regenerative medicine continues to advance, more patients are hearing about Dezawa MuseCells® and their unique biological properties. At the same time, the growing popularity of this technology has created an important challenge: products being marketed as "MUSE cells" that are not authentic Dezawa MuseCells®. In today's episode, we'll explain why authenticity matters, what questions patients should ask, and why scientific validation is more important than ever. When an innovative medical technology gains attention, it's common for similar products to enter the marketplace. Regenerative medicine is no exception. As awareness of Dezawa MuseCells® has increased, so has the number of products using the term "MUSE." However, the name alone does not guarantee authenticity. According to scientists involved with the development and study of the technology, if a product was not generated using Professor Mari Dezawa's validated derivation and characterization protocols, it should not be considered an authentic Dezawa MuseCell®. That distinction isn't about marketing. It's about scientific validation. Authentic Dezawa MuseCells® have been investigated through decades of laboratory research, preclinical studies, and clinical experience. Their biological characteristics have been documented using validated manufacturing methods and rigorous quality standards. One of the most remarkable characteristics described in the scientific literature is their ability to naturally home to damaged tissue. Unlike many other cellular products, authentic Dezawa MuseCells® respond to signals released by injured tissue and migrate to those locations without external guidance. This unique biological behavior is one of the reasons they continue to generate significant interest within the field of regenerative medicine. However, these characteristics cannot simply be assumed because another product carries a similar name. The defining properties associated with authentic Dezawa MuseCells® result from specific derivation, characterization, validation, and manufacturing processes. Without those validated methods, there is no scientific basis to conclude that another product possesses the same biological profile or safety characteristics. This is why patients should never hesitate to ask questions before receiving any regenerative medicine treatment. Ask whether the product being used is an authentic Dezawa MuseCell®. Ask whether it was generated using Professor Mari Dezawa's validated protocol. Ask whether the manufacturer can document the product's origin and quality standards. And ask what published scientific evidence supports the specific cellular product being offered. These are reasonable questions, and reputable providers should welcome them. Another important development is that patients no longer need to travel internationally to access authentic Dezawa MuseCells®. They are now available in the United States through MuseCell® Innovations licensed manufacturers, providing physicians with access to products produced under validated manufacturing standards. As interest in regenerative medicine continues to grow, education remains one of the most valuable tools patients have. Similar names do not necessarily represent similar science. A logo can be copied. A product name can be copied. Scientific validation cannot. Understanding that distinction can help patients make more informed decisions and have more meaningful conversations with their healthcare providers. Thank you for listening to The Miami Stem Cell Podcast, presented by STEMS Health. To learn more about regenerative medicine and authentic Dezawa MuseCells®, visit STEMS Health for additional educational resources. This podcast is provided for informational and educational purposes only and should not be considered medical advice. Individual treatment decisions should always be made in consultation with a qualified healthcare professional.

ep 43 What Actually Determines Success in Dezawa Muse Stem Cell Therapy?

To learn more about regenerative and restorative stem cell therapy treatments, visit www.stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565. ------------- What Actually Determines Success in Dezawa Muse Stem Cell Therapy? There is a gap in how regenerative medicine is often evaluated — by patients, by the industry, and sometimes by providers themselves. The conversation centers on what can be measured at the lab level: cell counts, processing standards, product certifications. These are visible. They are quantifiable. They are easy to compare. They are also, by themselves, remarkably poor predictors of whether a patient actually improves. At STEMS Health in Miami Beach, Drs. Ankeet Choxi and Jarred Mait have identified three factors that consistently differentiate patients who achieve meaningful outcomes from those who do not. None of them are lab metrics. All of them are clinical. The first is diagnostic precision. Dezawa Muse stem cells are not a broad-spectrum treatment for pain or degeneration. They are a targeted biological intervention with specific mechanisms — stress-guided homing, tissue-specific differentiation, immunomodulation. That targeting only works when the tissue being treated is correctly identified. A patient presenting with knee pain might have osteoarthritis, meniscal pathology, periarticular bursitis, or some combination. These are different conditions with different structural implications. Treating the wrong pathology — or treating the right pathology with an imprecise understanding of its extent — produces results that fall short of what the therapy is capable of. At STEMS Health, every protocol begins with a confirmed diagnosis. Imaging. Clinical correlation. Laboratory workup. The protocol is designed around that diagnosis — not around a symptom description or a generalized complaint. The second factor is injection technique. Even a well-characterized, high-potency Muse cell preparation achieves very little if it is not delivered accurately to the target tissue. Injection technique is a procedural skill that encompasses approach angle, imaging guidance, depth calibration, and the prevention of cellular leakage into non-target tissue. At STEMS Health, musculo-skeletal injections are performed under ultrasound guidance — real-time visualization that confirms the cells are deposited precisely at the intended site, whether that is within a joint capsule, a tendon sheath, a disc space, or a neural structure. That precision is not incidental to the therapy. It is the mechanism by which the cells reach the tissue that needs them. Without it, even a superior preparation becomes a clinical approximation. The third factor is post-procedure follow-up care. The injection is not the conclusion of treatment. It is the beginning of a biological process that unfolds over days, weeks, and months. Muse cells initiate cellular homing, differentiation, and tissue remodeling across an extended regenerative window. The clinical environment during that window directly influences how well those processes develop. Patients who receive an injection and then disengage from structured care consistently underperform compared to patients who remain engaged. At STEMS Health, follow-up is not a courtesy — it is a clinical protocol. Scheduled reassessments allow the treating physicians to monitor functional progress, adjust rehabilitation guidance, manage the anti-inflammatory environment appropriately, and identify early signals that warrant attention. Imaging follow-up is conducted when indicated to assess structural changes at the treatment site. Taken together, these three factors tell a consistent story. The lab produces the tool. The physician determines whether that tool reaches its target, in the right patient, with the right diagnosis, delivered with precision, and supported through the recovery window with clinical intent. When evaluating a regenerative medicine provider, patients are best served by asking not about lab credentials — but about the diagnostic process, the injection guidance protocol, and the structure of follow-up care. Those answers will reveal far more about the likely outcome than any comparison of cell counts or facility certifications. At STEMS Health, the sequence is consistent across every patient: diagnose with precision, design the protocol around that diagnosis, deliver with imaging guidance, and follow up with clinical purpose. That sequence is not a differentiator. It is the standard.

Ep 42 MSCs vs. Dezawa MUSEcells™: Understanding Dose, Value, and When Each Makes Sense

To learn more about regenerative and restorative stem cell therapy treatments, visit www.stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565. ------------- MSCs vs. Dezawa MUSEcells™: Understanding Dose, Value, and When Each Makes Sense If you've been looking into regenerative medicine, you've probably run into two terms a lot. Mesenchymal stem cells, or MSCs, and Dezawa MUSEcells. Your first question is probably the obvious one. Which one should I actually get? At STEMS Health, Drs. Ankeet Choxi and Jarred Mait get this question constantly. The honest answer is, it depends on your biology, your condition, and the dose required to get the job done. MSCs work through paracrine signaling. They release bioactive molecules that calm inflammation and support tissue repair across a broad area. They're not precise, but they're powerful when you need a wide, systemic effect. Dezawa MUSEcells are different. They're a distinct pluripotent cell population discovered by Dr. Mari Dezawa, and their defining trait is precision. They self-direct toward damaged tissue, responding to the body's own distress signals, and differentiate once they get there. Think of MSCs as a wide net, and MUSEcells as cells that already know where they're going. Here's where patients are usually surprised. A typical MSC protocol might use around fifty million cells. A Dezawa MUSEcells protocol often uses somewhere between ten and twenty five million. That's not because MUSEcells are a lesser therapy. It's because they work differently. Since they home directly to the site that needs them, you need fewer cells to get a comparable, or even better, result. That's also where the value conversation comes in. As an MSC dose climbs higher, the cost climbs with it. At a certain point, a much smaller dose of Dezawa MUSEcells becomes more efficient and more cost effective. That's not a sales discount. It's just what happens when you need far fewer cells to do the same work. That said, MUSEcells aren't automatically the better choice for everyone. Some conditions call for the broad effect a higher volume MSC protocol provides. Others are better served by the targeted, lower dose approach. So how do you know which one is right for you? That comes down to a structured evaluation, looking at your inflammatory baseline, your imaging at the treatment site, and your prior treatment history. That evaluation, not a default package, determines whether MSCs, Dezawa MUSEcells, or a specific dose of either, is the right fit. One more thing worth mentioning. Exosomes, tiny vesicles released by MSCs, are still part of the toolkit and may come up in your evaluation. But for most patients today, the real decision point is MSCs versus MUSEcells, with dose as the key variable. If you're trying to figure out where you fall in that comparison, the next step is a real evaluation with Drs. Choxi and Mait, not a guess based on a podcast. Reach out to STEMS Health to find out which path fits your biology. Disclaimer The information provided in this podcast episode is for educational and informational purposes only and is not intended as medical advice. Treatments and outcomes described may not be appropriate for every individual. Always consult a licensed healthcare provider to determine the best course of care for your specific needs. Certain regenerative medicine procedures discussed – such as stem cell therapy, exosome therapy, or other biologic treatments – may be considered investigational or not FDA-approved for all conditions. Florida law requires that we disclose this status. While these procedures are offered in accordance with state and federal guidelines, their safety and efficacy have not been fully established by the U.S. Food and Drug Administration. Results vary, and no guarantee of specific outcome or benefit is implied. All medical procedures involve potential risks, which should be discussed with your treating provider prior to treatment. © STEMS Health Regenerative Medicine, Miami Beach, Florida. All rights reserved.

Ep. 41 Does More Dezawa Muse Stem Cells Mean Better Results?

To learn more about regenerative and restorative stem cell therapy treatments, visit www.stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565. ------------- Does More Dezawa Muse Stem Cells Mean Better Results? In regenerative medicine, numbers move people. Cell counts appear in marketing materials, comparison charts, and patient forums. The assumption behind them is intuitive: more cells delivered to a damaged tissue should mean a stronger regenerative signal, a faster recovery, a better outcome. At STEMS Health in Miami Beach, Drs. Ankeet Choxi and Jarred Mait encounter this assumption constantly. And their clinical experience points to a different conclusion. Cell count is a data point. It is not a clinical outcome. What determines whether a Dezawa Muse stem cell preparation actually performs is not how many cells are in the vial. It is whether those cells are potent, whether they are viable, and whether they are being administered with physician-guided precision to a correctly identified target. Potency refers to a cell's functional capacity. Can it recognize and home to damaged tissue? Can it differentiate into the appropriate cell type once it arrives? Can it modulate the immune environment in a way that supports healing rather than triggering resistance? These are biological capabilities — not quantities. A preparation with a lower cell count but high potency, confirmed through strong SSEA-3 expression and robust differentiation markers, will outperform a high-volume, low-potency preparation in virtually every clinical scenario. Viability refers to how many of those cells are alive and metabolically active at the moment of injection. Cells lose viability during handling, transport, and storage. A preparation marketed at a high cell count may arrive at the injection site with a fraction of those cells actually capable of therapeutic activity. Dead cells produce no regenerative signal. They do not differentiate. They do not modulate. They simply occupy space in a protocol that the patient paid for and trusted. This is why the sourcing environment, processing standards, and delivery timing of a Muse cell preparation carry clinical weight. At STEMS Health, lab data on each preparation is reviewed before administration. Viability percentage, SSEA-3 positivity, differentiation capacity — these are not background details. They are part of the clinical decision. There is also a risk that runs counter to the more-is-better assumption. Introducing an excessive volume of biological material into the body without calibration to the patient's immune status, inflammatory baseline, and injury profile can trigger unintended inflammatory cascades. The goal of a regenerative protocol is not to maximize cell volume. It is to deliver cells that are fit to perform, in a quantity appropriate to the patient's individual biology, at a site that has been confirmed through diagnostic precision. At STEMS Health, every Muse cell protocol begins with a structured pre-treatment evaluation. The diagnosis is confirmed through imaging and clinical correlation. The patient's immune and inflammatory baseline is assessed. The preparation is reviewed for quality markers. The injection site is evaluated for anatomical targeting. Only when that evaluation is complete does the protocol take shape. That process cannot be replaced by a higher number on a marketing sheet. It requires a physician who understands what they are treating, why they are treating it, and what quality of biological material is being delivered into a body that is depending on that judgment. When patients evaluate regenerative medicine providers, the most important questions are not about volume. They are about potency, viability, diagnostic process, and physician-guided protocol design. Those are the variables that determine what happens after treatment. And at STEMS Health, those are the variables that guide every decision made before it. This is STEMS Health — regenerative medicine in Miami Beach, guided by clinical precision.